From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
Clinical data
Trade namesSimulect
License data
  • AU: D
ATC code
Pharmacokinetic data
Elimination half-life7.2 days
CAS Number
  • none
Chemical and physical data
Molar mass143801.68 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.


Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.[1] It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.[2]

Mechanism of action[edit]

Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[3][4]


It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[3][4]


It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[5]

See also[edit]

References and notes[edit]

  1. ^ MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
  2. ^ Katsambas AD, Lotti TM (2003). European handbook of dermatological treatments (2nd ed.). p. 291. ISBN 3-540-00878-0.
  3. ^ a b Hardinger KL, Brennan DC, Klein CL (July 2013). "Selection of induction therapy in kidney transplantation". Transplant International. 26 (7): 662–72. doi:10.1111/tri.12043. PMID 23279211. S2CID 3296555.
  4. ^ a b Basiliximab label
  5. ^ Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.